Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 176 to 199 of 500 messages
Chat Pages: Latest  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
16/7/2018
08:46
I took out stake @63 -- spread quoted was wide @60/66
bscuit
13/7/2018
22:53
Where is the resistance ?
the stigologist
13/7/2018
17:35
i'm hoping to top slice at 80p near term, possibly a tadge optimistic.....
kristini2
13/7/2018
17:23
Blimey.Close to major long term breakout. Could get silly the way it's melted up on news looks like informed buying in a very tight market. Holders are strong hands.
the stigologist
13/7/2018
17:02
Nice end to the week.Fig.
fig1
12/7/2018
13:38
There was scuttlebut a few years back about the Intensity investment alone being worth potentially 10x the SALV Market Cap No doubt been significant dilution since then but also substantial progress Could not see NAV figure in recent accounts but would expect it will be highly conservative and historic given accounting rules for such VC type investments
the stigologist
12/7/2018
10:49
witness the recent deal involving biogen and another, around dementia and funding-all creating a lot of interest in this sector....... jim mellon on the money again with his big theme ideas...
kristini2
12/7/2018
10:00
The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients.
the stigologist
12/7/2018
09:53
This has mega bag potential though with stakes in private US biotechs
the stigologist
12/7/2018
09:43
bio sector starting to get a bid and outperform i'm adding ; syncona nicely moving bio fund novartis and crispa both mellon tips will move up from here
kristini2
12/7/2018
09:24
Melting up on no news Extraordinary
the stigologist
11/7/2018
15:17
very underowned i guess
the stigologist
11/7/2018
10:09
Post results road show? Liquidity event coming ?
the stigologist
11/7/2018
00:20
Just melting up on the sly
the stigologist
01/7/2018
10:51
Outlook The main objective when we started this Company was to identify drugs/products that had interesting science behind them and that could benefit from our drug development and commercialization expertise. We have now been successful in sourcing a wide range of products from around the globe. Each has specific needs and challenges that our extended team has been focused on resolving. Not everything will go as planned, but the team has many years of experience in overcoming challenges, and finding creative solutions to push the programs forward. The real reward is trying to help give hope to cancer patients for whom the available drugs have failed and are in need of new options. I am reminded of how challenging this is as one of our investigators writes to me about a woman in her 30s with no other options who is eager to get into one of our trials. The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients. At the SalvaRx corporate level, we continue to identify potential investments or acquisitions. We expect to grow further by acquisition, investment or licensing arrangements as we identify novel cancer immunotherapies. Not all of our projects will progress, as we are continually prioritizing those with the highest probability of success. Dr lan Walters Chief Executive Officer 27 June 2018
the stigologist
01/7/2018
10:51
breaking out Golden Cross
the stigologist
27/6/2018
15:20
Amazing....+ almost 14% and all that on really quite small. Heaven only knows what the lift-up will be when the volume is really turned up. 30.6% at the lowest ask on show. Happy days! f
fillipe
05/5/2018
13:38
Satisfactory end to the week.
fig1
03/5/2018
08:15
No liquidity in the shares. Won't take much buying to get the price above 30p where it should be.
wiseacre
02/5/2018
12:46
Patience Fillipe, patience.
fig1
02/5/2018
12:41
SALV + 18% today, although seems to have dropped off the radars of most folks. f
fillipe
09/4/2018
17:21
Aren't immunotherapy related stocks out of favour right now- given some recent failings in the immunotherapy related process and sector ?
kristini2
05/4/2018
16:17
Actually dexdringle I think the stock is grossly undervalued but as far as the company is concerned it appears not to give a button, in terms of promotion here, and I have heard the American CEO, not only has a contempt for AIM, but, is looking to get the shares quoted his side of the Atlantic where biotech gets a better rating. With regard to my comment on the quality of investors I hardly think the promoter of the company at IPO, Peterhouse, has a great roster of long-term investors to get the stock away. Maybe you are one of them! No offence intended.
wiseacre
04/4/2018
14:39
"wiseacre 22 Mar '18 - 11:22 - 111 of 112 The problem is that those who subscribed at 33p, not the highest quality of investor......." Eh ? Why would investing at 33p not been a sign of being a high quality investor ? Presumably you were a genius and were shorting it from there (and are still doing so) thus making you a very high quality investor ? Unless all investors who buy something that goes down are poor quality investors - in which case please stand up the person who only ever buys things that go up !!
dexdringle
Chat Pages: Latest  8  7  6  5  4  3  2  1
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200119 17:29:41